These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Postmarketing surveillance and reporting of adverse drug events. Baer RK S D J Med; 2004 Jan; 57(1):13-4. PubMed ID: 14964975 [No Abstract] [Full Text] [Related]
43. The Food and Drug Administration's regulation of risk disclosure for implantable cardioverter defibrillators: has technology outpaced the Agency's regulatory framework? Basile EM; Lorell BH Food Drug Law J; 2006; 61(2):251-72. PubMed ID: 16903031 [No Abstract] [Full Text] [Related]
44. The marketplace can't give us the drug safety data we need. Avorn J MedGenMed; 2007 Feb; 9(1):29. PubMed ID: 17435636 [No Abstract] [Full Text] [Related]
45. Confidentiality laws and secrecy in medical research: improving public access to data on drug safety. Kesselheim AS; Mello MM Health Aff (Millwood); 2007; 26(2):483-91. PubMed ID: 17339677 [TBL] [Abstract][Full Text] [Related]
46. Drug approval system questioned in US and Canada. Eggertson L CMAJ; 2005 Feb; 172(3):317-8. PubMed ID: 15684107 [No Abstract] [Full Text] [Related]
47. The FDA and the tort system: postmarketing surveillance, compensation, and the role of litigation. Struve CT Yale J Health Policy Law Ethics; 2005; 5(2):587-669. PubMed ID: 16052895 [No Abstract] [Full Text] [Related]
48. Comparison of Duration of Postapproval vs Pivotal Trials for Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval, 2009-2018. Wallach JD; Ramachandran R; Bruckner T; Ross JS JAMA Netw Open; 2021 Nov; 4(11):e2133601. PubMed ID: 34751764 [TBL] [Abstract][Full Text] [Related]
49. Post-market approval surveillance: a call for a more integrated and comprehensive approach. Mehran R; Leon MB; Feigal DA; Jefferys D; Simons M; Chronos N; Fogarty TJ; Kuntz RE; Baim DS; Kaplan AV Circulation; 2004 Jun; 109(25):3073-7. PubMed ID: 15226222 [No Abstract] [Full Text] [Related]
50. Applications for Food and Drug Administration application approval to market a new drug; revision of postmarketing reporting requirements. Final rule. Food and Drug Administration, HHS Fed Regist; 2007 Oct; 72(201):58993-9000. PubMed ID: 17966558 [TBL] [Abstract][Full Text] [Related]
51. Post-marketing experience with an opioid nasal spray for migraine: lessons for the future. Loder E Cephalalgia; 2006 Feb; 26(2):89-97. PubMed ID: 16426261 [TBL] [Abstract][Full Text] [Related]
52. Making medicines safer--the need for an independent drug safety board. Wood AJ; Stein CM; Woosley R N Engl J Med; 1998 Dec; 339(25):1851-4. PubMed ID: 9854125 [No Abstract] [Full Text] [Related]
53. Regulatory framework for the availability and use of animal drugs in the United States. Modric S Vet Clin North Am Small Anim Pract; 2013 Sep; 43(5):1005-12. PubMed ID: 23890234 [TBL] [Abstract][Full Text] [Related]
54. Post-market drug safety evidence sources: an analysis of FDA drug safety communications. Ishiguro C; Hall M; Neyarapally GA; Dal Pan G Pharmacoepidemiol Drug Saf; 2012 Oct; 21(10):1134-6. PubMed ID: 23033257 [No Abstract] [Full Text] [Related]
55. Pharmacometrics at FDA: evolution and impact on decisions. Powell JR; Gobburu JV Clin Pharmacol Ther; 2007 Jul; 82(1):97-102. PubMed ID: 17538553 [TBL] [Abstract][Full Text] [Related]
56. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval. O'Reilly JT Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397 [No Abstract] [Full Text] [Related]
57. The FDA and drug safety: a proposal for sweeping changes. Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825 [TBL] [Abstract][Full Text] [Related]
58. Moment of reckoning. Wadman M Nature; 2007 Apr; 446(7138):844-5. PubMed ID: 17443154 [No Abstract] [Full Text] [Related]
59. Blowing the whistle at the FDA. Simons J Fortune; 2005 Jan; 151(2):32. PubMed ID: 15693304 [No Abstract] [Full Text] [Related]